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Summary
Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide
belonging to the IL-7/IL-9 family of proteins that bind to a composite
receptor consisting of the private receptor IL-9R and the IL-2 receptor,
gamma (IL-2RG), a common gamma subunit shared by the receptors of
many different cytokines. The IL-9R is expressed widely and IL-9 impacts a
number of effector cells, such as effector T cells, B cells, innate lymphoid
cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle
cells, playing an important role in regulating inflammatory immunity. The
critical role of IL-9 in promoting cellular and humoral immune responses
makes it an important focus of potential therapeutic interventions. Recently,
a defined subset of T helper type cells, Th9 cells, has been identified by the
potent production of IL-9. The involvement of the Th9 cell subset has been
described in many types of inflammatory diseases, namely atopic diseases,
helminth infections, experimental autoimmune encephalomyelitis and
ulcerative colitis. In this review, we summarize the IL-9 biological activities,
highlighting roles for IL-9 and Th9 cells in rheumatoid and psoriatic
arthritis, systemic vasculitis, systemic lupus erythematosus and systemic
sclerosis.
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Introduction
The role of CD41 T cells in the pathogenesis of rheumatic
diseases has been well established [1,2]. The differentiation
of naive CD4(1) T cells into different cell subsets with dis-
tinct biological activities is determined largely by their
interaction with dendritic cells (DCs) in lymphoid organs.
In particular, the development of a particular subtype of
functional T cells seems to be related to the interaction
with the surrounding microenvironment, which include
cellular interactions and the release of specific cytokines
and transcription factors [3,4]. Different subsets of CD41
T cells are defined usually by the specific expression of
transcription factors, cytokine receptors and their released
cytokines. T helper type 1 (Th1), Th2, Th17, T follicular
helper and derived regulatory T cells are well-known CD41
T cell subsets [4,5].
Interleukin (IL)-9, a cytokine with pleiotropic functions
in the immune system [6,7], was identified originally as a T
cell growth factor belonging to the common g-chain-
receptor cytokine family. IL-9 signals through a heterodi-
meric receptor composed by a specific IL-9 receptor chain
(IL-9Ra) and the common g-chain (also known as IL-
2Rg) [8]. IL-9Ra is expressed on immune cells and its acti-
vation also promotes mast cell growth [8,9] and accumula-
tion in inflamed tissues, innate lymphoid cells (ILC)
survival and B cell immunoglobulin (Ig)E class-switch
recombination [9–11] (Fig. 1 shows IL-9R-expressing
cells). IL-9Ra is also expressed on non-haematopoietic cells
such as airway and intestinal epithelial cells, smooth muscle
cells and keratinocytes [12,13].
IL-9 production was associated first with the Th2 pheno-
type and many of the preliminary functions of IL-9 were
studied in models of Th2-associated immunity. Recently, a
defined subset of T helper cells called Th9 has been identi-
fied by the potent production of IL-9 [14–16]. Th9 cells
develop from naive T cells in the presence of transforming
growth factor (TGF)-b, IL-4 and thymic stromal lympho-
poietin (TSLP) (Fig. 1) and require PU.1 and the interferon
regulatory factor-4 (IRF-4) as specific transcription factors
[7,17].
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Although a role of the Th9 cell subset has been described
recently in many types of inflammatory diseases (namely,
atopic diseases, helminthic infections, experimental auto-
immune encephalomyelitis and inflammatory bowel dis-
eases) [18,19], their role is still largely unknown in the
pathogenesis of rheumatic disease. This paper aims to
review the evidence indicating that Th9 cells may contrib-
ute to the pathogenesis of autoimmune-related diseases,
due to the recent demonstration of a possible role of Th9 T
cells and of their related cytokine IL-9 in rheumatoid
arthritis (RA), psoriatic arthritis (PsA), systemic vasculitis,
systemic lupus erythematosus (SLE) and systemic sclerosis
(SSc) [20–28] (Fig. 1 shows the possible tissue target of
Th9-mediated inflammation).
IL-9 signalling
IL-9 is a protein of 144 amino acids with a secretory signal
sequence of 18 amino acids. On target cells, IL-9 binds to
IL-9R, a heterodimeric protein composed by IL-9Ra
belonging to the haematopoietin superfamily, and the IL-
2R-g, a common subunit shared by different cytokine
receptors. Binding of IL-9 with the cognate receptors leads
to the activation of signal transducer and activator of
transcription-1 (STAT-1), STAT-3 and STAT-5 [29,30]. IL-
9R is expressed on effector T cells but not naive T cells.
Th2, Th17 and Th9 display the highest IL-9R expression.
In asthmatic patients IL-9R is also expressed on mast cells
and polymorphonuclear cells [31]. Several studies also sug-
gest the expression of IL-9R on lung and intestinal epithe-
lial cells and on the surface of smooth muscle cells (Fig. 1)
[31].
Th9 polarization
The differentiation of Th9 cells requires the activation of
IL-2/STAT-5 and IL-4/STAT-6 signalling and TGF-b, which
acts by inducing redirection of naive T cells from a Th2 to
Th9 cell differentiation pathway (in Fig. 1 it is summarized
the differentiation pathway of Th9 cells) [7]. It has been
demonstrated recently that, in primary cell cultures, the
addition of TSLP led to an increase in IL-9 production
from human and mouse Th9 cells, and induced an increase
in STAT-5 activation and binding to the IL-9 promoter
[31]. Th9 differentiation requires PU.1, IRF-4 and the B
cell activating transcription factor-like (BATF), as specific
transcription factors that bind to and activate the IL-9
locus [7]. Besides these cytokines, other signalling pathways
seem to act by enhancing IL-9 production by Th9 cells,
such as IL-25 and IL-33, by activating nuclear factor kappa
B (NF-jB), type I interferons and IL-1b by inducing STAT-
1/IRF-1 expression [7]. Furthermore, the interaction
between T cells and antigen-presenting cells (APC) through
the T cell receptor (TCR)/peptide–major histocompatibil-
ity complex (MHC) class II, CD28/CD80, OX40/OX40L,
NOTCH/DLL and Jagged may have an important role in
Th9 differentiation [7].
IL-9 and Th9 cells in RA
RA is a chronic autoimmune and inflammatory systemic
disease that primarily affects synovial joints. It is character-
ized by the aberrant expression of several proinflammatory
cytokines and recruitment of autoreactive lymphocytes
into inflamed tissues [32]. T and B cells are involved pre-
dominantly in the pathogenesis of RA, together with the
orchestrated interaction of proinflammatory cytokines
such as TNF-a, IL-6, IL-1b and IL-17 [32].
IL-9 has been demonstrated to be increased significantly
in the sera of RA patients not related to disease duration,
disease activity score (DAS28), health assessment question-
naire (HAQ), rheumatoid factor positivity or erosions on
radiography [25]. High levels of IL-9 have been also
detected in patients’ first-degree relatives’ sera with RA or
with asymptomatic RA-related autoimmunity [26,33]. Fur-
thermore, IL-9, together with IL-6, is the most responsible
in the cytokine score calculated by summing all cytokine/
chemokine levels, weighted by their regression coefficients
for RA–autoantibody association [26]. IL-9 levels are also
elevated significantly in the synovial fluid of RA patients
compared to osteoarthritis (OA) and IL-9 promotes prolif-
eration and survival of synovial fluid CD3(1) T cells of RA
patients, the proliferation of T cells being dependent upon
the PI3K/Akt/mTOR signalling pathway [34].
IL-9 has been reported to be over-expressed significantly
in synovial tissue of RA patients and correlated with the
degree of tissue inflammation [24]. IL-9 expression has
been found mainly among synovial fibroblasts and infil-
trating mononuclear cells. Th9 cells were demonstrated to
be the main source of IL-9 in both synovial tissues (Fig. 1)
and peripheral blood of RA, given the predominant co-
expression of IL-9 with PU.1 [24]. Th9 polarization in RA
synovium was accompanied by a significant up-regulation
of IL-4, TGF-b and TSLP correlated directly with the num-
ber of IL-9-positive cells. Interestingly, Th17 also produced
IL-9 in RA synovium, although to a lesser degree [24].
RA synovial tissue may display a different topographical
distribution of the inflammatory infiltrates: diffuse infil-
trates of inflammatory cells without aggregates of specific
microstructures, T and B cell aggregates without germinal
centre (GC) organization and aggregation of inflammatory
cells in secondary follicles with GC formation [32]. IL-9
and IL-9R expression has been proved to be correlated
directly with the degree of inflammatory infiltrate and
lymphoid organization in RA patients [24]. The strong
connection between IL-9/IL-9R axis activation and the
induction of autoimmune responses has been highlighted
recently due to the potential role of IL-9 in T cell-
dependent B cell differentiation, expansion and antibody
production [10], as well as by the evidence that IL-9R is
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expressed in GC B cells where its stimulation induces
STAT-5 activation [35]. The correlation between IL-9/IL-
9R and lymphoid organization could confirm the impor-
tance of IL-9- and IL-9-producing cells in the induction of
autoimmunity in RA.
Autoimmunity in RA is characterized by aberrant
immune responses to autoantigens that have been modified
post-translationally by citrullination [36,37]. Citrullinated
arthritogenic aggrecan peptide has been considered to be a
biomarker of RA, having been identified in the peripheral
blood of RA patients, and has shown to stimulate a specific
CD4 response [38–40]. It is considered a candidate autoan-
tigen for RA, being one of the principle proteoglycans for
cartilage extracellular matrix functioning in cushioning
synovial joints, self-antigens that share a common sequence
at position 70–74 of the human leucocyte antigen D-
related (HLA-DR) b-chain in 90% of RA patients [38,41].
In RA patients, stimulation with the arthritogenic aggrecan
peptide resulted in a strong and significant expansion of
Th9 cells. Together, these results suggest the existence of an
association between the emergence of autoreactive Th9
cells and the occurrence of synovial inflammation and cit-
rullination process [24].
IL-9 and Th9 cells in psoriatic arthritis
PsA is a chronic inflammatory disease affecting the spine
or peripheral joints of patients with psoriasis or with a pos-
itive personal or familial history of skin manifestations
[42]. PsA has long been considered as a Th1-mediated dis-
ease, with interferon (IFN)-g and IL-12 as signature cyto-
kines [43]. Recently, however, it has been shown that both
Fig. 1. T helper type 9 (Th9) cells develop from naive T cells in the presence of transforming growth factor (TGF)-b, interleukin (IL)-4 and
thymic stromal lymphopoietin (TSLP). Aberrant Th9 activation may cause the onset and progression of autoimmune and chronic inflammatory
diseases such as asthma, rheumatoid and psoriatic arthritis, chronic gut inflammation, kidney diseases, systemic vasculitides and systemic
sclerosis. MC 5 mast cells; Eo 5 eosinophils; Treg 5 regulatory T cells.
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innate and adaptive immunity, leading to the activation of
the IL-23/Th17 axis, may contribute to the initiation of tis-
sue inflammation [44–46]. More recently, IL-9 has been
also demonstrated to be involved in the pathogenesis of
psoriasis [47]. In particular, Th9 cells that are increased in
the skin lesions of psoriasis seem to have a specific tropism
for the skin and their aberrant activation may contribute to
skin inflammatory diseases [48].
Psoriasis and PsA have been demonstrated to be linked
strongly to gut inflammation [49]. Several studies have
highlighted the importance of subclinical gut inflammation
in spondyloarthropathy pathogenesis, indicating the
inflamed gut as the site where autoreactive and proinflam-
matory cells are activated and from which they are released
in the systemic circulation, with consequent localization in
extra-intestinal inflamed sites [50]. Few studies, however,
have addressed specifically the immune responses in the
gut of PsA patients.
PsA subclinical gut inflammation is characterized histo-
logically by a higher number of infiltrating inflammatory
cells, which are organized frequently in lymphoid follicles.
Immunologically, the ileum of PsA patients shows a clear
and defined IL-23/Th17 response, as shown by both IL-23
and IL-17 strong up-regulation, with a defective Th1 polar-
ization [50]. However, IL-9 seems to mark gut inflamma-
tion in PsA specifically, given the impressive IL-9
expression observed in the gut of PsA patients [27]. IL-9 is
produced particularly by inflammatory cells and epithelial
cells that were demonstrated to be Paneth cells (PC), as co-
expression of IL-9 and a-defensin 5 (a specific marker of
PC) has been observed. In PsA gut, PC also express the IL-
9R and after in-vitro stimulation with recombinant IL-9,
produce high levels of specific peptides such as a-defensin
5 and cytokines such as IL-23, indicating the occurrence of
an autocrine loop involving IL-9 [27]. PC are highly speci-
alized small intestine epithelial cells; they are located pre-
cisely at the bottom of Lieberk€uhn crypts and are involved
in innate immune responses and anti-microbial host
defence, thus contributing to the maintenance of the gas-
trointestinal barrier [51]. A specific microbiome signature
has been demonstrated recently in PsA patients, indicating
a role for dysbiosis in the pathogenesis of PsA [52]. The
specific release of IL-9 by PsA PC could be relevant in this
context, as it may represent a significant immune link
between innate and adaptive responses.
Th9 polarization also characterizes the synovium
(Fig. 1) and the peripheral blood of PsA patients, and the
percentage of circulating Th9 cells is correlated significantly
with disease activity [27]. Moreover, Th9 cells, isolated
from both synovium and peripheral blood of PsA patients,
express the intestinal homing receptor a4b7, indicating
that these cells are probably activated in the gut and recir-
culate into sites of inflammation [27]. Interestingly, we
have recorded that circulating Th9 cells in PsA decreased
after anti-TNF and ustekinumab treatment, leading us to
speculate that the clinical improvement observed in PsA
patients treated with these classes of drugs could be, at least
in part, referred to the modulation of Th9 response [27].
Together these findings indicate that PsA may be character-
ized by IL-9 and Th9 polarization, suggesting that these
cells may represent a future therapeutic target.
IL-9 and Th9 cells in large-vessel vasculitis
Large-vessel vasculitides (LVV) are characterized by the
autoimmune inflammation of medium and large arteries
leading to occlusion of the lumen with ischaemic damage
of dependent organs [53]. Several effector cytokines
involved in both innate and adaptive immunity have been
identified in vasculitic lesions [54]. However, among the
different immune pathways characterizing immune
responses, the IL-6–IL-17 axis and the IL-12–IFN-g axis
seem to play a fundamental role in LVV pathogenesis [54].
Giant cell arteritis (GCA) is the prototype of LVV and is
characterized by a range of histological patterns of vascular
wall injury [54]. Beyond the classic transmural inflamma-
tion (with or without giant cells), two other different histo-
logical aspects of GCA have been described [55]: small
vessel vasculitis (SVV) defined as inflammation of the small
vessels external to the temporal artery adventitia and vasa
vasorum vasculitis (VVV), defined as isolated inflamma-
tion of temporal artery vasa vasorum [55].
Th1 and Th17 subsets of effector T cells have been dem-
onstrated clearly to participate in the pathogenesis of GCA
[54,56]. Although Th2-derived cytokines have been dem-
onstrated previously to be consistently absent [54], the IL-
33 pathway seems to be over-expressed in the inflamed
arteries of GCA patients and accompanied by a strong M2
macrophage polarization [57]. Beyond the role in promot-
ing the Th2 response, IL-33 has also been associated
recently with the secretion of IL-9 by human CD41 T cells
isolated from peripheral blood [58–60], apparently indicat-
ing a potential role of Th9 cells in the pathogenesis of
GCA.
Analysis of IL-9 and IL-17 expression in different histo-
logical subsets of GCA has demonstrated that a different
immunological polarization characterizes different histo-
logical patterns of GCA [20]. The different expression of
cytokines in different patterns of tissue pathology may be
of immunological relevance. Multiple effector T cell subsets
(such as Th17 and Th9) may induce GCA independently of
each other, probably by overlapping but with distinct
mechanisms. IL-9 and Th9 cells, in fact, immunologically
mark the inflamed arteries of GCA patients with inflamma-
tion restricted to the peri-adventitial small vessels. Con-
versely, a more intense Th17 polarization, with weak IL-9
expression, predominates in the GCA arteries with inflam-
mation restricted to the vasa vasorum. Interestingly, a con-
comitant Th9 and Th17 response is observed in arteries
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displaying transmural inflammation and especially in those
arteries with granulomatous reaction [20].
Inflammatory cells infiltrating the artery wall, giant cells,
endothelial cells of vessels scattered through the inflammatory
infiltrates and among vascular smooth muscle cells showed
intense positivity for IL-9 [20]. IL-9 tissue expression was also
correlated significantly with the intensity of the systemic
inflammatory response, including erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) [20]. Infiltrating
inflammatory cells producing IL-9 were demonstrated to be
Th9 cells, considering the significant co-localization observed
between IL-9 and PU.1 (the specific transcription factor for
Th9 cells), suggesting the prevalent Th9 phenotype of IL-9
mononuclear-producing cells (Fig. 1). Notably, when present,
giant cells scattered in the inflamed arteries showed an intense
co-expression of IL-9 and IL-17 [20].
Th9 cells are a distinct subpopulation of CD41 effector
T cells that require TGF-b, IL-4 and TSLP for their differ-
entiation [7]. GCA arteries with higher expression of IL-9
(transmural inflammation with granulomatous reaction
and SVV) displayed intense over-expression of TGF-b, IL-4
and TSLP, suggesting that the upstream Th9 cytokine net-
work is also up-regulated in GCA [20]. The biological
effects of IL-9 are mediated by the functional IL-9 receptor
complex, that is composed of this protein as well as the IL-
2 receptor gamma (IL-2RG), a common gamma subunit
shared by the receptors of many different cytokines [7].
The activation of this receptor leads to the activation of
various Janus kinases (JAK) and STAT proteins [8] which
connect to different biological responses [6]. In GCA,
IL-9R positivity was observed among endothelial cells of
vessels distributed in the inflammatory infiltrates and neu-
trophils [20]. Functional expression of IL-9R receptor by
human neutrophils has been demonstrated in asthmatic
patients, with an important role in IL-8 release [61]. IL-9/
IL-9R over-expression in GCA was accompanied by a sig-
nificantly high expression of IL-8 and IL-8R, especially in
patients with transmural inflammation, providing a func-
tional immunological link between IL-9R expression and
neutrophil activity, thus highlighting the importance of
neutrophils in the pathogenesis of GCA [20].
Studies conducted on small series have shown previously
that IL-17A-expressing cells are reduced dramatically in
specimens obtained from glucocorticoid-treated patients
[56]. Differently from IL-17, IL-9 was modified only mar-
ginally by glucocorticoids. This apparent IL-9 low sensitiv-
ity to glucocorticoid inhibition may indicate a potential
role for Th9 cells in steroid-resistant GCA [20].
IL-9 and Th9 cells in anti-neutrophil cytoplasmic
antibodies (ANCA)-associated vasculitis
Granulomatosis with polyangiitis (GPA) is a systemic
necrotizing vasculitis that affects small- and medium-sized
vessels in many organs associated with granulomatous
inflammation and the presence of ANCAs directed against
proteinase 3 (PR3) [62,63]. PR3 has been demonstrated to
be expressed at the plasma membrane of neutrophils and
may act by interfering with induction of anti-inflammatory
mechanisms following phagocytosis of these cells by mac-
rophages and/or by facilitating anti-PR3 ANCA binding,
leading to neutrophil activation and consequent tissue
inflammation [64]. Interestingly, in different murine mod-
els, membrane-associated PR3 on apoptotic cells triggered
secretion of inflammatory cytokines and chemokines, thus
inducing a specific microenvironment instructing plasmo-
cytoid dendritic cells (pDC) to promote a specific effector
T cell subset. In particular, pDCs exposed to apoptotic cells
expressing membrane PR3 in a TGF-b-rich environment
induce the generation of Th9 cells. Th9 and Th2 cell polar-
ization [65]. Interestingly, PBMCs obtained from active,
untreated systemic GPA patients also displayed skewed Th9
and Th17 responses, revealing a GPA-specific mechanism
of immune polarization [65].
Th9 cells in systemic lupus erythematosus
SLE is a disorder of generalized autoimmunity character-
ized by the dysregulation of cellular and humoral immune
responses, the break in immune tolerance to self-antigens,
polyclonal B cell activation and the production of autoanti-
bodies. Autoantibody deposition and inflammatory cell
infiltration in target organs such as kidneys and brain char-
acterizes SLE. It has been reported that aberrant T lympho-
cyte activation and altered cytokine production are
important contributors to SLE pathogenesis. However, so
far the exact mechanisms that lead to the development of
SLE remain undefined.
Only few studies have been carried out on Th9 cells and
their related cytokine, IL-9, in human SLE. These studies
have shown an increase in the Th9 cell subset and IL-9
serum levels on active SLE. In lupus-prone mice Th9 cells
accumulated in the spleen and in the kidneys (Fig. 1) and
their number is related closely to the presence of germinal
centres [23]. In addition, in-vivo treatment with neutraliz-
ing anti-IL-9 antibodies was able to reverse serum anti-
dsDNA antibody levels [23].
IL-9 can be produced by different T cell subsets that
include CD81 cells, invariant natural killer T (NK T) cells,
gd T cells, Th17 cells and innate lymphoid cell group 2
(ILC2) [50–53]. IL-9 is also known to induce TH17 differ-
entiation and IL-17 production, and these cytokines may
work together synergistically in promoting SLE pathogene-
sis. Despite these observations, the role of Th9 and IL-9 in
SLE patients remains unclear.
IL-9 and Th9 cells in systemic sclerosis
Expression of IL-4, TGF-b and TSLP has been implicated
in fibrosis and remodelling in SSc [66–68]. Furthermore,
IL-9 in rheumatic diseases
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Th9 and IL-9 seem to increase tissue fibrosis, as demon-
strated in the liver, where IL-9 induces hepatic fibrosis and
an exacerbated disease end-point [69]. Serum IL-9 level has
been demonstrated to be increased in patients with SSc and
associated with a lower frequency and severity of pulmo-
nary fibrosis, indicating IL-9 as a protective factor in SSc
[28]. However, the presence of high IL-9 levels and the
strong expression of Th9 polarizing cytokines in SSc raise
the question of whether Th9 cells might participate in SSc
pathogenesis. In this regard, strong expression of IL-9 and
IL-9R has been demonstrated recently in skin tissue of
patients with diffuse SSc and correlated with the modified
Rodnan skin score and the presence of pulmonary fibrosis
[70]. In particular, IL-9 expression was observed mainly in
the context of infiltrating mononuclear cells and in the ker-
atinizing squamous epithelium of skin from SSc patients
[70]. The majority of IL-9-producing cells in the skin were
identified as Th9 and Th17 cells. Among peripheral blood
mononuclear cells, Th9 cells were the major source of IL-9,
being expanded significantly in SSc patients compared to
controls [70]. The participation of IL-9 and Th9 in the pro-
cess of inflammation and fibrosis action in SSc, however, is
still not clear, and further studies are required to better
clarify their role in modulating tissue fibrosis.
Conclusions
IL-9 and Th9 cells seem to be involved in the immunopa-
thology of several human diseases. In systemic rheumatic
diseases this axis is activated and involved potentially in the
triggering and/or maintaining inflammation. The targeting
of IL-9/Th9 cells could be considered a productive strategy
in treating systemic autoimmune diseases. However, fur-
ther studies are required to understand more clearly the
specific contribution of this axis in the pathogenesis of dif-
ferent systemic autoimmune diseases.
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